Philipp LASTEI
LightNews LightNews
banner
philipplastei.bsky.social
Philipp LASTEI
@philipplastei.bsky.social
35 followers 40 following 2 posts
Posts Replies Media Videos
Reposted by Philipp LASTEI
nejm.org
Presented at #SVIN25:

CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst
The Society of Vascular and Interventional Neurology 2025 Annual Meeting Original Article | NOV 21, 2025 | NEJM.org Medical Management and Revascularization for Asymptomatic Carotid Stenosis Figure 2A. Primary-Outcome Analysis. The NEJM signature sits at the bottom.
November 21, 2025 at 3:38 PM
Reposted by Philipp LASTEI
mattiasmandorfer.bsky.social
😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!)
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?

🖇️: rdcu.be/eLAde

#LiverSky @georg-semmler.bsky.social
November 8, 2025 at 3:02 AM
Reposted by Philipp LASTEI
nejm.org
The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which the authors review. Learn more: nej.md/4hwZMgj

#MedSky #GastroSky
Review Article Noninvasive Assessment of Liver Fibrosis Laurent Castera, M.D., Ph.D., Mary E. Rinella, M.D., and Emmanuel A. Tsochatzis, M.D., Ph.D. A figure showing the diagnosis, staging, and progression of liver fibrosis. The NEJM identity sits at the bottom.
October 29, 2025 at 10:00 PM
Reposted by Philipp LASTEI
lancetgastrohep.bsky.social
New research - Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

www.thelancet.com/journals/lan...

#GastroSky #MedSky
October 28, 2025 at 7:25 AM
philipplastei.bsky.social
„Beim Teutates“ #asterix41 - Asterix in Lusitanien - #outnow
October 23, 2025 at 6:02 PM
Reposted by Philipp LASTEI
arminwolf.at
Exzellenter Kommentar zur Absetzung von Late-Night-Host Jimmy Kimmel - und wie die Trump-Regierung Redefreiheit interpretiert: „Conservatives can say what they want, and everyone else can say what conservatives want.“
The Constitution Protects Jimmy Kimmel’s Mistake
Free speech is under assault.
www.theatlantic.com
September 18, 2025 at 4:09 PM
Reposted by Philipp LASTEI
nejm.org
MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as pharmacotherapies targeting the associated liver and cardiovascular–renal–metabolic issues. Learn more: nej.md/4lpS4F0

#MedSky #Nephrology
Review Article Metabolic Dysfunction–Associated Steatotic Liver Disease Giovanni Targher, M.D., Luca Valenti, M.D., and Christopher D. Byrne, M.B., Ch.B. Panel A: Factors related to insulin resistance and metabolic dysfunction, diet and environmental exposures, and genetic and epigenetic factors are the main drivers of MASLD development and its progression throughout the entire spectrum of liver disease. Panel B: Female sex and hormonal factors can also modulate the development and progression of MASLD.
August 13, 2025 at 10:00 PM
Reposted by Philipp LASTEI
reibergerthomas.bsky.social
Study by our #Liver #Team @meduniwien.ac.at
and @MedHochschuleHannover

Minimal residual ascites 3 months after #TIPS implantation implicates worse clinical outcome in patients with #liver #cirrhosis

published in @jhepatology.bsky.social #Reports

🔗 sciencedirect.com/science/arti...
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis
Transjugular intrahepatic portosystemic shunt (TIPS) implantation is indicated for recurrent/refractory ascites in patients with cirrhosis. The progno…
sciencedirect.com
June 4, 2025 at 6:12 AM
philipplastei.bsky.social
Carvedilol preferred NSBB in PHT

• Reduces vascular resistance too
• Start: 6.25 mg once daily
• Titrate to 6.25 mg BID
• Max dose: 12.5 mg/day
• Maintain SBP ≥90 mmHg
• No endoscopy if on therapy

#DDW25
May 4, 2025 at 6:55 PM
Reposted by Philipp LASTEI
nejm.org
In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-pressure target of less than 120 mm Hg than with a target of less than 140 mm Hg. Full trial results and Research Summary: nej.md/4eyDckd

#MedSky #CardioSky
The New England Journal of Medicine Intensive Blood-Pressure Control in Patients with Type 2 Diabetes A Research Summary based on Bi Y et al. | 10.1056/NEJMoa2412006 | Published on November 16, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
March 31, 2025 at 7:50 PM
Reposted by Philipp LASTEI
thelancet.com
Understanding colorectal cancer screening behaviour is key to increasing uptake.

In our latest issue, a recent trial evaluates the impact of two behavioural interventions on uptake of FIT colorectal screening.

Find this & more 👉 tinyurl.com/y9sjj4hc
Cover of the March 29, 2025 issue of The Lancet. Quote on cover reads: “Our findings show the potential for low-cost or no-cost behavioural interventions to increase participation in screening and reduce deaths from colorectal cancer [by] adding one sentence to the invitation letter.”
March 28, 2025 at 12:36 PM
Reposted by Philipp LASTEI
amcollegegastro.bsky.social
In #CTGjournal:

Secondary SBP Prophylaxis is Associated with a Higher Rate of Non-SBP Infections in Two US-based National Cirrhosis Cohorts
Silvey, et al.

➡️ bit.ly/428BEKH
@jasmohanbajaj.bsky.social
March 15, 2025 at 6:23 PM
Reposted by Philipp LASTEI
reibergerthomas.bsky.social
Systemic inflammation🔥(SI) is a major driver of #liver disease progression in patients with decompensated #cirrhosis.
Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels.
🔗 t.ly/A39-U
March 6, 2025 at 1:22 PM
Reposted by Philipp LASTEI
amergastroassn.bsky.social
Our latest clinical practice update offers 1️⃣1️⃣ tips to help you evaluate and manage portal vein thrombosis in cirrhosis patients. Watch @drjessicadavis.bsky.social and Fadi Francis discuss management strategies. https://buff.ly/40Y66Wc

#Cirrhosis #Liversky
February 21, 2025 at 2:00 PM
Reposted by Philipp LASTEI
arminwolf.at
Der offizielle X-Account des Weißen Hauses heute Abend.
Es wird praktisch stündlich irrer.
February 19, 2025 at 9:06 PM
Reposted by Philipp LASTEI
mattiasmandorfer.bsky.social
Challenge for #liversky :
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)
February 15, 2025 at 10:49 AM
Reposted by Philipp LASTEI
thelancet.com
Over 400 million people globally are affected by alcohol use disorder.

In @lancetgastrohep.bsky.social, a new Review explores the current management and treatment options for alcohol use disorder from a gastroenterology and hepatology-focused perspective: tinyurl.com/43fxj63f
Figure showing therapies in alcohol use disorder and their neurobiological basis. Copyright: Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
February 19, 2025 at 12:05 PM